Evidence map›Paper›PMID 26237380›Full record

ReviewJournal of clinical medicine2014

The Power and the Promise of Cell Reprogramming: Personalized Autologous Body Organ and Cell Transplantation.

Ana Belen Alvarez Palomo, Michaela Lucas, Rodney J Dilley, Samuel McLenachan, Fred Kuanfu Chen, Jordi Requena, Marti Farrera Sal, Andrew Lucas, Inaki Alvarez, Dolores Jaraquemada and 1 more

Open access · goldAbstract readReview
In one paragraph

Review in Journal of clinical medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Neurogenic tissue nanotransfection in the management of cutaneous diabetic polyneuropathy.Nanomedicine : nanotechnology, biology, and medicine · 2020
    Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 2 countries.

Ana Belen Alvarez PalomoControl of Pluripotency Laboratory, Department of Physiological Sciences I, Faculty of Medicine, University of Barcelona, Hospital Clinic, Casanova 143, Barcelona 08036, Spain. b.alvarez@ub.edu.
Michaela LucasSchool of Medicine and Pharmacology, University of Western Australia, Crawley, Perth, WA 6009, Australia. michaela.lucas@health.wa.gov.au.
Rodney J DilleyEar Sciences Centre, School of Surgery, University of Western Australia, Nedlands, WA 6009, Australia. rodney.dilley@uwa.edu.au.
Samuel McLenachanCentre for Ophthalmology and Visual Science (Lions Eye Institute), University of Western Australia, Perth, WA 6009, Australia. samuelmclenachan@lei.org.au.
Fred Kuanfu ChenCentre for Ophthalmology and Visual Science (Lions Eye Institute), University of Western Australia, Perth, WA 6009, Australia. fredchen@lei.org.au.
Jordi RequenaControl of Pluripotency Laboratory, Department of Physiological Sciences I, Faculty of Medicine, University of Barcelona, Hospital Clinic, Casanova 143, Barcelona 08036, Spain. joreos@hotmail.com.
Marti Farrera SalControl of Pluripotency Laboratory, Department of Physiological Sciences I, Faculty of Medicine, University of Barcelona, Hospital Clinic, Casanova 143, Barcelona 08036, Spain. marti.farrera@gmail.com.
Andrew LucasInstitute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Perth, WA 6150, Australia. a.lucas@iiid.com.au.
Inaki AlvarezImmunology Unit, Department of Cell Biology, Physiology and Immunology and Institute of Biotechnology and Biomedicine, Universitat Autònoma de Barcelona, Bellaterra 08193, Spain. inaki.alvarez@uab.es.
Dolores JaraquemadaImmunology Unit, Department of Cell Biology, Physiology and Immunology and Institute of Biotechnology and Biomedicine, Universitat Autònoma de Barcelona, Bellaterra 08193, Spain. dolores.jaraquemada@uab.es.
Michael J EdelControl of Pluripotency Laboratory, Department of Physiological Sciences I, Faculty of Medicine, University of Barcelona, Hospital Clinic, Casanova 143, Barcelona 08036, Spain. michaeledel@ub.edu.
Universitat de Barcelona · ESLions Eye Institute · AUUniversitat Autònoma de Barcelona · ESMurdoch University · AUPathwest Laboratory Medicine · AUUniversity of Sydney · AUUniversity of Western Australia · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Reprogramming somatic cells to induced pluripotent stem cells (iPSCs) or direct reprogramming to desired cell types are powerful and new in vitro methods for the study of human disease, cell replacement therapy, and drug development. Both methods to reprogram cells are unconstrained by the ethical and social questions raised by embryonic stem cells. iPSC technology promises to enable personalized autologous cell therapy and has the potential to revolutionize cell replacement therapy and regenerative medicine. Potential applications of iPSC technology are rapidly increasing in ambition from discrete cell replacement applications to the iPSC assisted bioengineering of body organs for personalized autologous body organ transplant. Recent work has demonstrated that the generation of organs from iPSCs is a future possibility. The development of embryonic-like organ structures bioengineered from iPSCs has been achieved, such as an early brain structure (cerebral organoids), bone, optic vesicle-like structures (eye), cardiac muscle tissue (heart), primitive pancreas islet cells, a tooth-like structure (teeth), and functional liver buds (liver). Thus, iPSC technology offers, in the future, the powerful and unique possibility to make body organs for transplantation removing the need for organ donation and immune suppressing drugs. Whilst it is clear that iPSCs are rapidly becoming the lead cell type for research into cell replacement therapy and body organ transplantation strategies in humans, it is not known whether (1) such transplants will stimulate host immune responses; and (2) whether this technology will be capable of the bioengineering of a complete and fully functional human organ. This review will not focus on reprogramming to iPSCs, of which a plethora of reviews can be found, but instead focus on the latest developments in direct reprogramming of cells, the bioengineering of body organs from iPSCs, and an analysis of the immune response induced by iPSC-derived cells and tissues.

Indexed as

autologousdirect cell reprogrammingimmune responseiPSCorgan bioengineering

Identifiers

PMID26237380
PMCPMC4449681
OpenAlexW2105659418

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.